Goldman Maintains Sell on Johnson & Johnson (JNJ); Drug Business Spin Still Unlikely
Goldman Sachs maintained a Sell rating on Johnson & Johnson (NYSE: JNJ) with a price target of $80.00. Analyst Jami ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)